ライフサイエンスコーパス: activation syndrome

1 whom 2 eventually developed overt macrophage activation syndrome).

2 hagocytic lymphohistiocytosis and macrophage activation syndrome.

3 scular coagulation as features of macrophage activation syndrome.

4 tablished, and 1 patient had a monoclonal MC activation syndrome.

5 fe-threatening condition known as macrophage activation syndrome.

6 ic mastocytosis but not monoclonal mast cell activation syndrome.

7 promising diagnostic markers for macrophage activation syndrome.

8 with those in patients with acute macrophage activation syndrome.

9 dentify patients with subclinical macrophage activation syndrome.

10 ssociated with the development of macrophage activation syndrome.

11 ning sample was diagnosed with monoclonal MC activation syndrome.

12 tionship between systemic JIA and macrophage activation syndrome.

13 bances in cytokine signaling, and macrophage activation syndromes.

14 arthritis is the association with macrophage activation syndrome, a life-threatening complication cau

15 anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, dissem

16 gulation and the relation between macrophage activation syndrome and hemophagocytic lymphohistiocytos

17 rstanding of the relation between macrophage activation syndrome and other clinically similar hemopha

18 in the last decade, many areas of mast cell activation syndrome are in need of research.

19 n sera from 7 patients with acute macrophage activation syndrome complicating systemic JIA and 16 pat

20 ha and sCD163 in diagnosing acute macrophage activation syndrome complicating systemic juvenile idiop

21 Hence, sepsis patients with macrophage activation syndrome features may benefit from interleuki

22 andomized trial using features of macrophage activation syndrome for mortality risk stratification sh

23 (including those with subclinical macrophage activation syndrome) from those with normal or only mode

24 Clinically, macrophage activation syndrome has strong similarities with familia

25 ytokines that are associated with macrophage activation syndrome/hemophagocytic lymphohistiocytosis,

26 uccessful use of cyclosporine for macrophage activation syndrome in JRA.

27 useful tool for identifying early macrophage activation syndrome in patients with systemic JIA.

28 n, pathogenesis and management of macrophage activation syndrome in systemic onset juvenile idiopathi

29 elucidate the pathophysiology of macrophage activation syndrome in systemic onset juvenile idiopathi

30 in expression may be a feature of macrophage activation syndrome in systemic-onset juvenile rheumatoi

31 ute to the increased incidence of macrophage activation syndrome in these patients.

32 A total of 335 patients presenting with MC activation syndrome, including 143 insectISMs(-), 72 ISM

33 clinical features of established macrophage activation syndrome, including ferritin levels.

34 Macrophage activation syndrome is a life-threatening complication s

35 Macrophage activation syndrome is characterized by an overwhelming

36 Macrophage activation syndrome is the rheumatic disease-associated

37 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar diseases charact

38 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are both characterized by dysr

39 The deadly macrophage activation syndrome (MAS) constitutes one of the few rhe

40 HLH, using modified HLH-2004 and macrophage activation syndrome (MAS) criteria.

41 Macrophage activation syndrome (MAS) is a devastating cytokine stor

42 Macrophage activation syndrome (MAS) is an acute episode of overwhe

43 The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a l

44 Macrophage activation syndrome (MAS), a major cause of morbidity an

45 ytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).

46 -onset recurrent fever flares and macrophage activation syndrome (MAS).

47 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).

48 -targeting drugs, the diagnosis of mast cell activation syndrome (MCAS) is appropriate.

49 proposed to interpret acute MCT in mast cell activation syndrome (MCAS).

50 Primary mast cell activation syndromes (MCAS) are a group of disorders pre

51 hagocytic lymphohistiocytosis and macrophage activation syndrome, natural killer and cytotoxic cell d

52 The macrophage activation syndrome occurred in 7 patients; infections w

53 om showed evidence of subclinical macrophage activation syndrome (of whom 2 eventually developed over

54 nal mast cell disorder (monoclonal mast cell activation syndrome or systemic mastocytosis) and thus c

55 n disorders (inflammasomopathies), NF-kappaB activation syndromes, protein misfolding disorders, comp

56 Mast cell activation syndrome refers to a group of disorders with

57 these 5 patients developed overt macrophage activation syndrome several months later.

58 sIL-2Ralpha in the patients with macrophage activation syndrome was 19,646 pg/ml (interquartile rang

59 level of sCD163 in patients with macrophage activation syndrome was 23,000 ng/ml (IQR 14,191), compa

60 herISMs(-)), 56 ISMs(+), and 64 nonclonal MC activation syndrome, were studied.

61 A monoclonal mast cell activation syndrome with aberrant mast cells (MC) at ext